Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + raltitrexed
- Development stage
- Unknown
- Lead developer
- First Hospital of China Medical University
- Modality
- Small Molecules
- Administration
- Intravenous, Intra-arterial
01
Overview
epirubicin + raltitrexed is a combination chemotherapy regimen consisting of the anthracycline epirubicin and the thymidylate synthase inhibitor raltitrexed. This combination is primarily investigated and utilized in the treatment of primary liver cancer (hepatocellular carcinoma), frequently administered via transarterial chemoembolization (TACE). Epirubicin acts by intercalating into DNA and inhibiting DNA topoisomerase II, which leads to DNA strand breaks and apoptosis. Raltitrexed is a quinazoline folate analogue that specifically and potently inhibits thymidylate synthase (TS), resulting in the depletion of thymidine triphosphate and the subsequent inhibition of DNA synthesis. Clinical research, notably from institutions such as The First Hospital of China Medical University, has evaluated this combination for its efficacy in improving local control and survival outcomes in patients with unresectable liver cancer.
- Brand names
- EllencePharmorubicinTomudex
- Other names
- rhetitrexelretitrexedepirubicin hydrochlorideraltitrexed
02
Targets
DNATOP2A (DNA topoisomerase II)TS (Thymidylate synthase)
Beyond the preview
Go deeper on epirubicin + raltitrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + raltitrexed.